The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

546 documents

  • J. Balosso, J.L. Habrand, Gerard Montarou, R. Ferrand, D. Dauvergne. France HADRON: national infrastructure for hadrontherapy research including ETOILE, ARCHADE and protontherapy centers. ICTR-PHE 2014, Feb 2014, Genève, Switzerland. ⟨hal-01052734⟩
  • R. Rescigno, J. Baudot, S. Brons, D. Dauvergne, C. Finck, et al.. Proton Interaction Vertex Imaging for carbon therapy quality control. ICTR-PHE 2014, Feb 2014, Genève, Switzerland. pp.S81. ⟨hal-01052753⟩
  • C. Abellan, J.-P. Cachemiche, D. Dauvergne, C. Morel, F. Réthoré, et al.. A μTCA Data Acquisition System and its application for Hadrontherapy Monitoring using a Compton Camera. ICTR-PHE 2014, Feb 2014, Genève, Switzerland. pp.S1. ⟨hal-01052729⟩
  • P. Manescu, Joseph Azencot, M. Beuve, H. Ladjal, B. Shariat. 4D dose calculations and 4D PET image reconstruction using deformable tetrahedral models of moving organs. ICTR-PHE 2014, Feb 2014, Genève, Switzerland. pp.S62. ⟨hal-01052873⟩
  • M. Pinto, D. Dauvergne, N. Freud, J. Krimmer, Jean Michel Létang, et al.. Research and development of a TOF-based multi-slit collimated camera for online hadrontherapy monitoring. ICTR-PHE 2014, Feb 2014, Genève, Switzerland. pp.S76. ⟨hal-01052748⟩
  • Gérald Bertrand, Mira Maalouf, Antony Boivin, Priscillia Battiston-Montagne, Michael Beuve, et al.. Targeting Head and Neck Cancer Stem Cells to Overcome Resistance to Photon and Carbon Ion Radiation. Stem Cell Reviews and Reports, 2014, 10 (1), pp.114-126. ⟨10.1007/s12015-013-9467-y⟩. ⟨hal-00871540⟩
  • V. Reithinger, L. Balleyguier, J. Baudot, M. Dahoumane, D. Dauvergne, et al.. Instrumentation pour le suivi en ligne des traitements par hadronthérapie. Nicole Jaffrezic-Renault. Instrumentation et Interdisciplinarité, Capteurs Chimiques et Physiques, EDP sciences édition, pp.169-175, 2014, Intégrations des Savoirs et des Savoir-faire. ⟨hal-00974587⟩
  • M.-A. Chanrion, W. Sauerwein, U. Jelen, A. Wittig, R. Engenhart-Cabillic, et al.. The influence of the local effect model parameters on the prediction of the tumor control probability for prostate cancer. Physics in Medicine and Biology, 2014, 59, pp.3019-3040. ⟨10.1088/0031-9155/59/12/3019⟩. ⟨hal-00990873⟩
  • F.C.L. Crespi, A. Bracco, R. Nicolini, D. Mengoni, L. Pellegri, et al.. Isospin Character of Low-Lying Pygmy Dipole States in Pb208 via Inelastic Scattering of O17 Ions. Physical Review Letters, 2014, 113, pp.012501. ⟨10.1103/PhysRevLett.113.012501⟩. ⟨in2p3-01071782⟩
  • G. Dedes, M. Pinto, D. Dauvergne, N. Freud, J. Krimmer, et al.. Assessment and improvements of Geant4 hadronic models in the context of prompt-gamma hadrontherapy monitoring. Physics in Medicine and Biology, 2014, 59 (7), pp.1747-1772. ⟨10.1088/0031-9155/59/7/1747⟩. ⟨hal-00967197⟩